SCHEMBL4609805

SCHEMBL4609805

COC(=O)c1ccc(NC(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.79
RAB9A P51151 7/20 0.79
MAPT P10636 4/20 0.77
ALDH1A1 P00352 3/20 0.77
ATM Q13315 1/20 0.73
TDP1 Q9NUW8 1/20 0.71
PTPN1 P18031 1/20 0.69
SMN1; SMN2 Q16637 5/20 0.66
PSMD14 O00487 1/20 0.61
CACNA1B Q00975 1/20 0.61
APBA1 Q02410 1/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
TP53 P04637 2/20 0.61
ALOX15 P16050 1/20 0.61
KDM4E B2RXH2 1/20 0.60
LMNA P02545 1/20 0.60
TSHR P16473 1/20 0.60
HSD17B10 Q99714 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610131 1.00 NPC1 (0.79) NPC1RAB9AMAPTALDH1A1ATM
SCHEMBL6263820 0.93 NPC1 (0.83) NPC1RAB9AMAPTALDH1A1ATM
SCHEMBL8660366 0.93 NPC1 (0.83) NPC1RAB9AMAPTALDH1A1ATM
SCHEMBL27181403 0.89 RAB9A (1.00) NPC1RAB9AMAPTALDH1A1TDP1
SCHEMBL15214321 0.89 RAB9A (1.00) NPC1RAB9AMAPTALDH1A1TDP1
SCHEMBL14580374 0.89 RAB9A (1.00) NPC1RAB9AMAPTALDH1A1TDP1
SCHEMBL822378 0.89 RAB9A (1.00) NPC1RAB9AMAPTALDH1A1TDP1
SCHEMBL12310125 0.89 RAB9A (1.00) NPC1RAB9AMAPTALDH1A1TDP1
SCHEMBL4113098 0.87 MAPT (1.00) NPC1RAB9AMAPTALDH1A1ATM
SCHEMBL7232750 0.86 KDM4E (0.74) NPC1RAB9AMAPTALDH1A1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3019615-B1 CYSTOBACTAMIDES HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) 2021-04-07 EP disclosed
EP-3049387-B1 THERMOPLASTIC POLYMER COMPOSITION MILLIKEN & CO (US) 2020-11-11 EP disclosed
EP-1660437-B1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2008-10-15 EP disclosed
US-7282522-B2 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2007-10-16 US disclosed
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof AMOREPACIFIC CORPORATION (KR) 2006-11-09 US disclosed
EP-1660437-A4 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORP (KR) 2006-09-20 EP disclosed
EP-1660437-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF Amorepacific Corporation (KR) 2006-05-31 EP disclosed
WO-2005019162-A1 HYDROXAMIC ACID DERIVATIVES AND THE METHOD FOR PREPARING THEREOF AMOREPACIFIC CORPORATION (KR) 2005-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252834-A1 Hydroxamic acid derivatives and the method for preparing thereof HDAC7, SIRT7, HCAR1 NPC1 2347/4885RAB9A 4487/4885MAPT 4563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.